News
-
-
COMMUNIQUÉ DE PRESSE
Prolocor to Present New Clinical Evidence at ACC 24 Supporting the Use of PLATELET FCɣRIIA (PFCG) as a Key Tool in Individualizing Dual Antiplatelet Therapy (DAPT)
Prolocor, Inc. announces acceptance of abstract on platelet FcγRIIa implications in myocardial infarction treatment strategy at ACC Scientific Sessions 2024
